• Citer

Metabolizing status of CYP2C19 in response and side effects to medications for depression: Results from a naturalistic study

par Calabrò, Marco;Fabbri, Chiara;Kasper, Siegfried S.F.;Zohar, Joseph;Souery, Daniel ;Montgomery, Stuart;Albani, Diego;Forloni, GianLuigi Luigi G.;Ferentinos, Panagiotis;Rujescu, Dan;Mendlewicz, Julien ;De Ronchi, Diana;Serretti, Alessandro;Crisafulli, Concetta
Référence European neuropsychopharmacology, 56, page (100-111)
Publication Publié, 2022-03

Article révisé par les pairs

• Détails
• Contenu

Titre:	Metabolizing status of CYP2C19 in response and side effects to medications for depression: Results from a naturalistic study
Auteur:	Calabrò, Marco; Fabbri, Chiara; Kasper, Siegfried S.F.; Zohar, Joseph; Souery, Daniel; Montgomery, Stuart; Albani, Diego; Forloni, GianLuigi Luigi G.; Ferentinos, Panagiotis; Rujescu, Dan; Mendlewicz, Julien; De Ronchi, Diana; Serretti, Alessandro; Crisafulli, Concetta
Informations sur la publication:	European neuropsychopharmacology, 56, page (100-111)
Statut de publication:	Publié, 2022-03
Sujet CREF:	Neurologie
	Psychiatrie
	Pharmacologie
	Physiopsychologie et psychologie biologique [psychiatrie]
Mots-clés:	Adverse effects
	Antidepressive agents
	CYP2C19
	Cytochrome P450
	Metabolism
	Pharmacogenetics
	Treatment outcome
Note générale:	SCOPUS: ar.j
	DecretOANoAutActif
Langue:	Anglais
Identificateurs:	urn:issn:0924-977X
	info:doi/10.1016/j.euroneuro.2022.01.008
	info:pii/S0924977X22000165
	info:scp/85124424606